ArticlePediatric pulmonology2025
Estimating the Effects of Continuous Albuterol Dosage on Clinical Outcomes for Pediatric Critical Asthma Exacerbation: A Retrospective Cohort Study.
Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Effectiveness of High-Flow Nasal Cannula and Bilevel Positive Airway Pressure in Children with Critical Asthma - A Systematic Review and Meta-Analysis.Indian journal of pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionPediatric asthma exacerbations sometimes require aggressive intervention including continuous albuterol, a cornerstone therapy for reversing airway obstruction. However, pediatric dosing typically follows adult guidelines, with limited evidence for specific dosing ranges. This study aimed to compare the clinical outcomes of a reduced initial dose (10 mg/h) of continuous albuterol with a standard dose (15 mg/h) in children hospitalized for critical asthma exacerbations.
methodsThis retrospective cohort study was conducted at Riley Hospital for Children, analyzing pediatric patients (ages: 2-18) admitted with critical asthma exacerbations between 2014 and 2022. Stabilized inverse probability weighting (SIPW) was used to adjust for confounding factors between groups. The primary outcome was the percentage change in the Pediatric Asthma Severity Score (PASS) at 24 h, with secondary outcomes including the duration of continuous albuterol, PICU length of stay, and hospital length of stay.
resultsAnalysis of 1,486 encounters revealed no significant difference in percent PASS changes at 24 h between the 10 mg/h and 15 mg/h groups (Additive Treatment Effect of 1.69, 95% CI: -0.93-4.31, p = 0.207). PICU and hospital lengths of stay were also similar. However, the 10 mg/h group showed a significantly shorter duration of continuous albuterol therapy compared to the 15 mg/h group (Multiplicative Treatment Effect of 1.29, 95% CI: 1.14-1.45, p < 0.001).
conclusionsFindings suggest that starting continuous albuterol at 10 mg/h provides clinical outcomes comparable to 15 mg/h in managing pediatric critical asthma exacerbations. A lower starting dose may optimize resource use and reduce treatment-related adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.